STOCK TITAN

electroCore (ECOR) Stock News

ECOR NASDAQ

electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.

Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.

Rhea-AI Summary

electroCore (Nasdaq: ECOR) announced online publication in Neuromodulation of a randomized study evaluating non-invasive nerve stimulation for Long COVID. The four-week study compared cervical vagus nerve stimulation, Sonocea’s acoustic stimulation, their combination and monitoring alone. Of 541 enrolled participants, 250 met final analysis criteria.

Depressive symptom scores decreased approximately 33% with electroCore’s technology, 31% with Sonocea’s and 34% with both, versus approximately 2% with monitoring alone. Each active group improved significantly from baseline; changes over time differed significantly across groups. Active treatments also showed improvements across other symptom domains. Direct comparisons found no significant differences among active treatments. Findings are hypothesis-generating: the study was open-label, lacked a sham control and relied primarily on patient-reported outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.39%
Tags
covid-19
-
Rhea-AI Summary

electroCore (ECOR) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026. The event will take place at The Westin New York Grand Central in New York City. Joshua Lev, Co-Chief Executive Officer, President and Chief Financial Officer, will present and host one-on-one investor meetings throughout the day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
Rhea-AI Summary

electroCore (Nasdaq: ECOR) reported third-quarter 2026 revenue of $9.7 million, up approximately 12% from the same period last year. GAAP net loss narrowed to $1.339 million, or $0.13 per share, from $3.405 million, or $0.40 per share. Gross margin rose to 88.5% from 86.0%, while U.S. prescription revenue grew approximately 25%.

The company revised its full-year 2026 revenue outlook to $39 million–$42 million, replacing guidance for greater than 30% growth. It introduced preliminary 2027 revenue growth guidance of 30%–40% and expects its first positive adjusted EBITDA quarter by the end of 2027. This outlook includes potential Quell label expansion, subject to FDA clearance; an October application seeks clearance for chronic chemotherapy-induced peripheral neuropathy, or nerve damage. Cash, cash equivalents and marketable securities totaled approximately $7.5 million, versus approximately $11.6 million at year-end 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
Rhea-AI Summary

electroCore (ECOR) will report its third-quarter financial results after the market closes on November 4, 2026. The results cover the quarter ended September 30, 2026. Management will host a conference call and webcast at 4:30 PM EST that day to review results and answer questions. A webcast replay will be available in the Investors section of the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
earnings date
-
Rhea-AI Summary

electroCore (Nasdaq: ECOR) submitted a 510(k) notification to the FDA seeking clearance of Quell for chronic chemotherapy-induced peripheral neuropathy (CIPN).

The submission draws on 168 subjects in a randomized controlled trial and an open-label study. Neuropathic pain scores decreased approximately 40% with active treatment versus approximately 24-33% with sham treatment. A non-pre-specified analysis of subjects with moderate to severe baseline pain showed decreases of approximately 50% versus approximately 30%.

In the 142-subject randomized trial, neuropathy questionnaire scores improved 11.6% with Quell versus 8.7% with sham, meeting the preliminary study’s pre-specified statistical significance threshold of 0.2. In the open-label study, 22 completers showed 13% improvement over six weeks. Quell-related adverse events were generally infrequent, mild and self-limiting. FDA clearance remains pending.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
none
-
Rhea-AI Summary

electroCore (ECOR) announced U.S. Air Force Research Laboratory findings suggesting its non-invasive neck nerve stimulation technology supports complex visual learning.

The controlled, five-day study divided 50 healthy airmen equally between active and sham stimulation using gammaCore Sapphire during training. Brain imaging showed greater activation in visual-learning areas on Day 2 with active stimulation (p<0.05). Later sessions showed lower task-related activation, interpreted as reduced executive demand. Behavioral modeling suggested better coordination between sequential tasks rather than a simple increase in average performance. Machine-learning analyses also identified distinct brain-activity patterns, suggesting possible changes in information processing after training.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.30%
Tags
none
Rhea-AI Summary

electroCore (Nasdaq: ECOR) will present at Planet MicroCap Toronto 2026 on October 28 at the Arcadian Court & Loft. Co-CEO, President and CFO Joshua Lev will deliver the presentation at 9:30 am ET and host one-on-one investor meetings throughout the October 27–29 conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
none
-
Rhea-AI Summary

electroCore (ECOR) will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York.

On Tuesday, September 15, 2026, Co-CEO, President and CFO Joshua Lev will take part in a fireside chat and hold one-on-one meetings with investors. Investors seeking a meeting are asked to contact their H.C. Wainwright sales representative or email electroCore Investor Relations at investors@electrocore.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
Rhea-AI Summary

electroCore (ECOR) appointed internal executives Joshua Lev and Mike Fox as Co-Chief Executive Officers and Board members, effective September 8, 2026.

The board chose a shared leadership structure after a succession process in which both candidates were viewed as capable CEOs whose complementary strengths had already been demonstrated working together. Lev, with the company since 2020 and most recently Interim President and Chief Financial Officer, will continue to oversee strategy, accounting, financial planning, investor relations, as well as R&D, product development and regulatory functions. Fox, who joined as Chief Operating Officer in April 2026, will lead commercial areas including sales, marketing and new market development across prescription and general wellness business lines.

The company said the co-CEOs will jointly steer overall strategy, culture, performance and long-term growth, with a focus on expanding its indication pipeline, accelerating revenue growth, opening new commercial channels and ultimately achieving positive adjusted EBITDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
Rhea-AI Summary

electroCore (Nasdaq: ECOR) announced that its wellness brand Truvaga, which uses patented non-invasive vagus nerve stimulation (nVNS) technology, has been named the 2026 Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards.

The recognition highlights Truvaga’s handheld nVNS devices, designed for general wellness and intended to support relaxation, stress management, sleep quality, focus and overall wellbeing via convenient two-minute sessions through gentle neck stimulation of the vagus nerve. According to electroCore, the award also reflects Truvaga’s intuitive product design, educational resources, high-touch customer support and complimentary one-on-one consultations that aim to help consumers confidently integrate nervous system wellness into daily life.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
none

FAQ

What is the current stock price of electroCore (ECOR)?

electroCore (ECOR) last closed at $5.17.

What is the market cap of electroCore (ECOR)?

The market cap of electroCore (ECOR) is approximately $47.7M.